Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions

Roxane Laboratories

Status and phase: Completed; Phase 1

Conditions: Trichomoniasis

Treatments: Drug: Tinidazole

Study type: Interventional

Funder types: Industry

Identifiers

NCT01591889

TINI-T500-PVFD-1

Details and patient eligibility

About

The objective of this study was to prove the bioequivalence of Roxane Laboratories' Tinidazole 500 mg Tablet under fed conditions.

Enrollment: 28 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening

Exclusion criteria

• Positive test for HIV, Hepatitis B, or Hepatitis C.
• Treatment with known enzyme altering drugs.
• History of allergic or adverse response to tinidazole or any comparable or similar product.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

28 participants in 2 patient groups

tindamax

Active Comparator group

Description:

500 mg tablet

Treatment:

Drug: Tinidazole

Drug: Tinidazole

tinidazole

Active Comparator group

Description:

500 mg tablet

Treatment:

Drug: Tinidazole

Drug: Tinidazole